Innoviva(INVA) - 2025 Q2 - Quarterly Results

Innoviva Reports Second Quarter 2025 Financial Results; Highlights Recent Company Progress Strong royalties portfolio performance with $67.3 million in revenue IST achieved U.S. net product sales of $29.0 million, reflecting 54% year-over-year growth ZEVTERA (ceftobiprole medocaril sodium, for injection) launched in the U.S. Zoliflodacin NDA accepted by FDA with Priority Review; PDUFA date set for December 15, 2025 BURLINGAME, Calif. – August 6, 2025 – Innoviva, Inc. (NASDAQ: INVA) ("Innoviva" or the "Compa ...